(Oct 8) Vaxart, Inc shares are up 7% in premarket trading after publishing results in an animal model that its COVID-19 vaccine pill can reduce airborne transmission of SARS-CoV-2.
Hamsters were vaccinated orally or intranasally with the vaccine candidate and then exposed to high levels of the COVID-19 virus to promote vaccine breakthrough. Vaccinated hamsters cleared the virus in the nose and lungs quickly.
But before clearing the infection, vaccinated hamsters were exposed to unvaccinated hamsters. The vaccinated hamsters infected fewer hamsters and created less severe clinical symptoms than did unvaccinated hamsters.
Results were published in BioRxiv, and have yet to be peer-reviewed.
Vaxart yesterday began recruitment in a phase 2 trial of the oral COVID vaccine.
精彩评论